

type of report	Current report
number	50/2012
company	PHARMENA

Share capital increase of Cortria Corporation

The Management Board of PHARMENA S.A. informs that on 28th August 2012, the Issuer increased share capital of subsidiary company Cortria Corporation by 400,000 USD (through the issue of 4,000 new shares). The increase is financed from Issuer's own funds.

The objective of the issue is to conclude production of tablets containing 1-MNA, preparing and submitting of application to Health Canada on commencing bioavailability testing of innovative anti-atherosclerosis medicinal product (1-MNA), and financing current operations of Cortria (patent fees, legal services, patent services, accounting services). The production of tablets containing 1-MNA and conducting bioavailability testing is indispensable for further clinical trials on anti-atherosclerosis medicinal product 1-MNA. Cortria Corporation will carry out this research in Canada.

Cortria Corporation is a private pharmaceutical company with registered headquarters in USA, which conducts clinical trials focusing on developing safe and well-tolerated medicinal products for the treatment of cardiovascular diseases, particularly atherosclerosis.

The information is made public due to the fact that concluding the processes of tablets' production and conducting 1-MNA bioavailability testing is significant for further clinical trials on anti-atherosclerosis medicinal product and commercialisation of that project. Potential revenue resulting from the commercialisation of anti-atherosclerosis medicinal product may have significant influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board